Ramucirumab

No information is available on the clinical use of ramucirumab during breastfeeding. Because ramucirumab is a large protein molecule with a molecular weight of about 147,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Until more data become available, ramucirumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during ramucirumab therapy and for 2 months after the last dose.